The Effect of Irrisept for Irrigation of Skin and Soft Tissue Infections (Irrisept USF Study)

Stopped early · Not applicable

Conditions studied: Skin and Soft Tissue Infections, Abscess

In brief

The purpose of this study was to determine whether Irrisept can effectively prevent the progression of skin and soft tissue infections (SSTIs) as compared to treatment by the current Standard of Care.

Key facts

Study ID

NCT01076049

Run by

Irrimax Corporation

People needed

114

Starts

2010-01-01

Expected to finish

2011-12-01

Last updated by the study team

2021-08-23

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 to 80
• Skin and soft tissue infections (SSTIs), in the form of an abscess, which will require incision and drainage.
• Patient able to provide an informed consent.
• Patient volunteers to participate.

You may not qualify if…

• Wound was caused by human or animal bite.
• Wound is a blunt crush injury or has tendon, bone, or joint involvement.
• Diabetic foot infection.
• Anticipated incision size less than 5mm.
• Abscess extends to the muscle layer.
• Admission to hospital for any reason, including IV antibiotics.
• Clinical signs of systemic infection on initial patient encounter.
• Prior history of allergy or hypersensitivity to CHG.
• Neutropenic (known ANC<500/mm3), HIV (known CD4<50), or other severely immunocompromised state (e.g., receiving chemotherapy).
• Patient is diagnosed with systemic lupus erythematosus or other immunological disease.
• Currently in police custody.
• Patient withdraws from participation.
• Patient unable or unwilling to give informed consent.

Where it is running

• Tampa General Hospital - University of South Florida — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.